We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has argenex SE (ARGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is a member of the Medical sector. This group includes 1019 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. argenex SE is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARGX's full-year earnings has moved 82.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ARGX has returned about 38% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 9.6% on average. This shows that argenex SE is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is ANI Pharmaceuticals (ANIP - Free Report) . The stock has returned 10.8% year-to-date.
For ANI Pharmaceuticals, the consensus EPS estimate for the current year has increased 4.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, argenex SE is a member of the Medical - Biomedical and Genetics industry, which includes 498 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has gained an average of 0% so far this year, meaning that ARGX is performing better in terms of year-to-date returns. ANI Pharmaceuticals is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on argenex SE and ANI Pharmaceuticals as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Argenx (ARGX) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has argenex SE (ARGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is a member of the Medical sector. This group includes 1019 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. argenex SE is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARGX's full-year earnings has moved 82.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ARGX has returned about 38% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 9.6% on average. This shows that argenex SE is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is ANI Pharmaceuticals (ANIP - Free Report) . The stock has returned 10.8% year-to-date.
For ANI Pharmaceuticals, the consensus EPS estimate for the current year has increased 4.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, argenex SE is a member of the Medical - Biomedical and Genetics industry, which includes 498 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has gained an average of 0% so far this year, meaning that ARGX is performing better in terms of year-to-date returns. ANI Pharmaceuticals is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on argenex SE and ANI Pharmaceuticals as they attempt to continue their solid performance.